The use of the AstraZeneca vaccine to protect against COVID-19 in Spain will be widened to include people aged 66-69, the health ministry announced Thursday. Amid fears the jab may cause blood clots, the government had on Wednesday limited the vaccine to 60-65 year-olds. “The aim is to complete the inoculation of the people who
Italy will reserve AstraZeneca’s vaccine for the over 60s following concerns of a link to blood clots in younger people, the government’s top adviser on the coronavirus crisis announced Wednesday. The decision has been taken to “recommend the preferential use on individuals aged above 60”, Franco Locatelli told reporters. His announcement came hours after the
Moderna vaccine: Unpaid carer receives first UK jab When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Moderna vaccine: Unpaid carer receives first UK jab When you subscribe we will use the information you provide to send you these newsletters. Sometimes they’ll include recommendations for other related newsletters or services we offer. Our Privacy Notice explains more about how we use your data, and your rights. You can unsubscribe at any time.
Italy will resume administering AstraZeneca/Oxford coronavirus vaccines on Friday after the EU’s drugs regulator declared them safe, Prime Minister Mario Draghi said. Italy suspended the use of the jab on Monday, one of a number of European countries taking precautionary action following concerns it was linked to blood clots. “The administration of the AstraZeneca vaccine
This is a landmark study in so far as being the first to raise the alarm that, despite early successes with COVID-19 vaccines, further research is warranted on a next generation of COVID-19 vaccines. The results from this study, however, only indicate that the AstraZeneca vaccine does not have at least 60% efficacy against mild-moderate
Germany, France and Italy on Monday became the latest countries to suspend use of AstraZeneca’s COVID-19 vaccine over reports of dangerous blood clots in some recipients, though the company and European regulators have said there is no evidence the shot is to blame. AstraZeneca’s formula is just one of three vaccines in use on the
BRUSSELS (Reuters) – AstraZeneca’s new aim to supply 30 million doses of its COVID-19 vaccine to the European Union by the end of March hinges on the bloc’s drug regulator approving supplies from a factory in the Netherlands, an internal document showed.FILE PHOTO: A test tube labelled “vaccine” in front of an AstraZeneca logo in
Europe’s medicines watchdog said Wednesday a preliminary probe showed that a batch of AstraZeneca vaccines used in Austria was likely not to blame for the death of a nurse who received a jab. Austria on Monday announced it would stop using doses from the batch, made by the British-Swedish firm with Oxford University, after the
The news reached Sarah Gilbert Saturday evening that the Covid-19 vaccine she’s developed with AstraZeneca Plc appeared to work. But the University of Oxford professor had expected a key number: Was it more than 90% effective, as others have been — or less? Instead, when her colleague Andrew Pollard called with the results, he wanted
